Alder's eptinezumab meets in Phase III to prevent chronic migraine

Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) reported top-line data from the Phase III PROMISE 2 trial in 1,072 patients with chronic migraine showing that 100 and 300 mg IV eptinezumab (IV ALD403) at weeks zero and